By Adriano Marchese
Elevation Oncology shares halted from trading in premarket trading Thursday after it said it will launch strategic options process and lay off the majority of its staff to extend its cash runway.
Shares halted at 48 cents in premarket trading. Shares are down about 15% year-to-date and 89% over the past 52 weeks.
The oncology company said that it has elected to discontinue its EO-3021 drug candidate, an antibody-drug conjugate being developed to treat advanced forms of gastric and gastroesophageal junction cancers.
The decision was made after the drug showed low response rate in its first trial phase.
Elevation also said that it will slash about 70% of its workforce, which is expected to cost the company about $3 million, and that it will launch a process to evaluate strategic options to maximize shareholder value.
The company still has a drug in the development pipeline, and said it will continue to advance EO-1022 to treatment patients with certain type of solid tumors.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 20, 2025 08:25 ET (12:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。